Get started
Author

Natalia Fernández Núñez

Observed names: Fernández Nuñez, Natalia, Fernández Núñez Natalia, N. Fernandez Nunez, N. Fernandez Nuñez, N. Fernández Nunez, N. Fernández Núnez, N. Fernández Núñez, N. Fernández-Núñez, Natalia Fernandez Nunez, Natalia Fernandez Nuñez, Natalia Fernandez-Nuñez, Natalia Fernández-Núñez
ORCID: 0000-0002-6503-395X
Observed ORCID: 0000-0002-6503-395X
OpenAlex ID: A5083202299
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Robert J. Motzer, Camillo Porta, et al. · Journal of Clinical Oncology · 222
Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience
2018 · Mª Carmen Areses Manrique, Joaquín Mosquera Martínez, et al. · Translational Lung Cancer Research · 64
PDF
Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy
2019 · Juan Ruiz-Bañobre, María C. Areses-Manrique, et al. · Translational Lung Cancer Research · 57
PDF
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
2022 · Martin J. Edelman, Mikhail Dvorkin, et al. · Lung Cancer · 51
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
2021 · J. Ruiz-Bañobre, A. Molina-Díaz, et al. · ESMO Open · 47
PDF
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
2020 · Jorge García-González, Juan Ruiz-Bañobre, et al. · Journal of Clinical Medicine · 29
PDF
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
2021 · Mariano Provencio, Josefa Terrasa, et al. · BMC Cancer · 17
PDF
A Primary Signet Ring Cell Carcinoma of the Prostate With Bone Metastasis With Impressive Response to FOLFOX and Cetuximab
2012 · Ana Milena Roldán, Natalia Fernández Núñez, et al. · Clinical Genitourinary Cancer · 15
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
2024 · Urbano Anido-Herranz, Ovidio Fernandez-Calvo, et al. · Frontiers in Oncology · 10
Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group
2020 · David Arias Ron, Maria Carmen Areses Manrique, et al. · Journal of Geriatric Oncology · 7
PDF
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
2018 · U. Anido-Herranz, N. Fernández-Núñez, et al. · Clinical & Translational Oncology · 5
PDF
Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer
2025 · María Carmen Areses Manrique, Luis León-Mateos, et al. · Clinical & Translational Oncology · 3
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
2022 · Guillermo de Velasco, Teresa Alonso-Gordoa, et al. · Clinical Genitourinary Cancer · 3
Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group
2025 · Natalia Fernández-Díaz, María Mateos-González, et al. · BMC Cancer · 2
PDF
Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study
2025 · Miguel A. Climent, Ricardo Sanchez-Escribano, et al. · Journal of Geriatric Oncology · 2
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
2025 · Cristina Suárez, Òscar Reig Torras, et al. · Clinical Genitourinary Cancer · 2
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish ‘Cambados annual meeting’
2025 · Ignacio Peláez, Martín Lázaro-Quintela, et al. · Clinical & Translational Oncology · 2
803TiP Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients
2020 · M.A. Climent Duran, L. Basterretxea, et al. · Annals of Oncology · 2
Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study
2025 · Natalia Fernández Núñez, Martín Lázaro Quintela, et al. · Cancer Treatment and Research Communications · 1
Radium-223 for mCRPC, a real-world experience study from 7 Galician medical centers.
2023 · Urbano Anido Herranz, Ovidio Fernandez Calvo, et al. · Journal of Clinical Oncology · 1
PDF
A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus
2020 · S. Vázquez Estévez, U. Anido, et al. · Clinical & Translational Oncology · 1
Efficacy and safety of Crizotinib in patients with ALK positive non small cell lung cancer (NSCLC): Real-world findings.
2019 · Cristina Azpitarte Raposeiras, Noemi De Dios Alvarez, et al. · Journal of Clinical Oncology · 1
Galician lung cancer group: Afatinib´s data as first-line treatment for elderly patients.
2019 · Sara Agraso Busto, Vanesa Varela, et al. · Journal of Clinical Oncology · 1
Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.
2019 · Juan Ruiz Bañobre, María C. Areses Manrique, et al. · Journal of Clinical Oncology · 1
Phase II trial of carboplatin and pemetrexed combination in elderly patients with advanced non-squamous non small cell lung cáncer (NS-NSCLC). A Galician Lung Cancer Group Study.
2015 · Mª Carmen Areses Manrique, Natalia Fernández Núñez, et al. · Journal of Clinical Oncology · 1
Works count: 52
Citation count: 547
H-index: 9
I10-index: 9
Year
Topic
Type